

April 15, 2015



Syros Pharmaceuticals to Present New Data from its Gene Control Platform in AML and Breast Cancer at AACR Annual Meeting 2015

- Research demonstrates how the comprehensive mapping of gene regulatory regions can illuminate clinically relevant subtypes and new therapeutic targets -

WATERTOWN, Mass.--(BUSINESS WIRE)-- [Syros Pharmaceuticals](#), a therapeutics company focused on discovering and developing novel gene control therapies, announced today that it will present two posters at the [American Association for Cancer Research \(AACR\) Annual Meeting 2015](#) in Philadelphia, which begins April 18.

Syros' platform identifies the gene control programs that control cell state and survival in different tumor cells. The two posters demonstrate that these gene regulatory programs can be mapped in primary patient samples and that such mapping recapitulates known clinical subtypes (in breast cancer) and can be used to discover new subtypes (in acute myeloid leukemia (AML)). This knowledge may be translated into the identification of new patient-specific anti-cancer drugs and targets in both AML and breast cancer.

"This research further demonstrates the value of our platform for identifying patient-specific cancer dependencies and gene control targets that form the basis for new therapeutic approaches," said [Eric Olson](#), PhD, Syros' Chief Scientific Officer.

Details for the two AACR posters from Syros are as follows:

- "Super-enhancer landscapes specify molecular subtypes and novel targets in acute myeloid leukemia;" Abstract #2212; Monday, April 20, 2015, 1:00-5:00 p.m.; Section 12; Poster Board #23.
- "Super-enhancers define breast cancer subclasses and identify novel tumor cell vulnerabilities;" Abstract #3837; Tuesday, April 21, 2015, 1:00-5:00 p.m.; Section 4; Poster Board #20.

About Syros Pharmaceuticals

Syros Pharmaceuticals is a therapeutics company harnessing breakthroughs in gene control to revolutionize the treatment of cancer and other diseases. Syros' proprietary platform identifies the master switches for disease genes, opening a whole new approach to novel therapeutics and biomarkers. The Company's founders are pioneers in gene control research and translation. Co-founded by Flagship Ventures and ARCH Venture Partners, Syros Pharmaceuticals is located in Watertown, MA. For more information, visit www.syros.com.

Sam Brown Inc.
Mariesa Kemble, 608-850-4745
mariesakemble@sambrown.com

Source: Syros Pharmaceuticals